You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 22, 2025

Patent: 10,059,765


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,059,765
Title:Methods and compositions for increasing the efficiency of therapeutic antibodies using NK cell potentiating compounds
Abstract: The present invention relates, generally, to methods and compositions for increasing the efficiency of therapeutic antibodies. Their efficiency is enhanced through the increase of the ADCC mechanism. More particularly, the invention relates to the use of a therapeutic antibody in combination with compounds that block an inhibitory receptor or stimulate an activating receptor of an NK cell in order to enhance the efficiency of the treatment with therapeutic antibodies in human subjects.
Inventor(s): Velardi; Andrea (Perugia, IT), Romagne; Francois (La Ciotat, FR)
Assignee: INNATE PHARMA S.A. (Marseilles, FR)
Application Number:14/789,548
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

Understanding the Patent Landscape: A Comprehensive Analysis of US Patent 10,059,765

Introduction

Patents are a cornerstone of innovation, providing inventors and companies with the exclusive rights to their inventions. The United States Patent and Trademark Office (USPTO) plays a crucial role in evaluating and granting these patents. This article will delve into the specifics of US Patent 10,059,765, analyzing its claims, the broader patent landscape, and the implications of recent USPTO guidance updates.

Overview of US Patent 10,059,765

To begin with, it is essential to understand the specifics of the patent in question. However, since the exact details of US Patent 10,059,765 are not provided, we will use general principles and recent trends in patent law to frame our analysis.

Patent Allowance Rates

The probability of receiving a US patent is not as high as often perceived. A study by Carley, Hegde, and Marco analyzed 2.15 million utility patent applications filed between 1996 and 2005 and found that only 55.8% of these applications were granted without using continuation procedures[1].

Technology Fields and Allowance Rates

The allowance rates vary significantly across different technology fields. For instance, applications in the "Drugs and Medical Instruments" and "Computers and Communications" fields have seen a substantial decrease in allowance rates over time[1]. This trend highlights the increasing scrutiny and complexity in these fields.

Patent Subject Matter Eligibility

One of the critical aspects of patent law is subject matter eligibility, particularly under 35 U.S.C. § 101. Recent updates to the USPTO guidance, effective July 17, 2024, have refined the process for determining the patent eligibility of AI-related inventions. The update emphasizes evaluating whether a claim integrates a judicial exception into a practical application, ensuring that the claimed invention offers a concrete technological improvement[2].

AI-Assisted Inventions

The 2024 USPTO guidance clarifies that the method of invention development, including the use of AI, does not impact subject matter eligibility. Instead, the focus remains on the claimed invention itself, ensuring that AI-assisted inventions are evaluated on equal footing with other technologies. This distinction is crucial as it ensures that AI’s role as a tool does not exclude inventions from eligibility, provided there is significant human contribution[2].

Practical Applications and Patent Eligibility

To meet the criteria for patent eligibility, claims must demonstrate a practical application that goes beyond mere abstract ideas. For example, in the context of AI, a claim involving an artificial neural network designed to identify anomalies can meet eligibility criteria by showing an improvement in computer technology. This is illustrated in Example 48 of the USPTO guidance, where specifying the use of separated audio components in a real-time speech recognition system enhances the accuracy of voice commands, thereby providing a tangible benefit[2].

Disclosure Requirements for AI Tools

The use of AI tools in patent applications introduces new complexities. If an AI tool is material to patentability, its use must be disclosed to the USPTO. This includes assessing whether the contributions made by natural persons rise to the level of inventorship, especially when AI systems assist in drafting portions of the specification and claims[5].

Geographical and Organizational Trends

Patent filings can also be analyzed through geographical and organizational lenses. For instance, studies on quantum computing patents have highlighted the leading countries and organizations in this field, as well as the impact of geopolitical factors on the development and patenting of quantum technologies[3].

Implications for Innovators and Patent Practitioners

The updated USPTO guidance and the evolving patent landscape have significant implications for innovators and patent practitioners. The guidance provides a clearer framework for evaluating the patent eligibility of AI-related inventions, ensuring that valuable technological advancements receive appropriate patent protection. By incorporating detailed examples and recent case law, the update aims to enhance the predictability and transparency of the patent examination process[2].

Patent Infringement Litigation

The increase in patent infringement lawsuits, particularly around significant changes in patent law such as the Leahy-Smith America Invents Act (AIA), underscores the importance of robust patent strategies. Stakeholders have identified factors such as the anticipation of legal changes and the limitations on the number of defendants in a lawsuit as contributing to the rise in litigation[4].

Key Takeaways

  • Patent Allowance Rates: Only about 55.8% of utility patent applications are granted without continuation procedures.
  • Subject Matter Eligibility: Recent USPTO guidance emphasizes the integration of judicial exceptions into practical applications for AI-related inventions.
  • AI-Assisted Inventions: The method of invention development, including AI, does not impact subject matter eligibility if there is significant human contribution.
  • Disclosure Requirements: The use of AI tools must be disclosed if material to patentability.
  • Geographical and Organizational Trends: Patent filings reflect broader technological and geopolitical trends.

FAQs

Q: What is the overall allowance rate for US patent applications? A: Approximately 55.8% of utility patent applications are granted without using continuation procedures[1].

Q: How does the USPTO evaluate the patent eligibility of AI-related inventions? A: The USPTO evaluates whether the claim integrates a judicial exception into a practical application, ensuring the claimed invention offers a concrete technological improvement[2].

Q: Do AI tools impact the subject matter eligibility of an invention? A: No, the method of invention development, including the use of AI, does not impact subject matter eligibility if there is significant human contribution[2].

Q: What are the disclosure requirements for using AI tools in patent applications? A: If an AI tool is material to patentability, its use must be disclosed to the USPTO, including assessing whether the contributions made by natural persons rise to the level of inventorship[5].

Q: How have recent changes in patent law affected patent infringement litigation? A: Changes such as the Leahy-Smith America Invents Act have influenced the number and nature of patent infringement lawsuits, with stakeholders identifying factors like the anticipation of legal changes and limitations on defendants[4].

Sources

  1. Carley, M., Hegde, D., & Marco, A. (2015). What Is the Probability of Receiving a US Patent? Yale Journal of Law & Technology, 17, 203-206.
  2. Mintz. (2024). Understanding the 2024 USPTO Guidance Update on AI Patent.
  3. Stanford Law. Quantum Leap: Decoding Quantum Computing Innovation.
  4. GAO. (2013). Assessing Factors That Affect Patent Infringement Litigation.
  5. BIPC. (2024). U.S. Patent Office Issues Additional Guidance on Use of AI Tools.

More… ↓

⤷  Try for Free

Details for Patent 10,059,765

ApplicantTradenameBiologic IngredientDosage FormBLAApproval DatePatent No.Expiredate
Genentech, Inc. RITUXAN rituximab Injection 103705 November 26, 1997 ⤷  Try for Free 2023-07-24
Genzyme Corporation CAMPATH alemtuzumab Injection 103948 May 07, 2001 ⤷  Try for Free 2023-07-24
Genzyme Corporation LEMTRADA alemtuzumab Injection 103948 November 14, 2014 ⤷  Try for Free 2023-07-24
Genzyme Corporation CAMPATH alemtuzumab Injection 103948 October 12, 2004 ⤷  Try for Free 2023-07-24
Genentech, Inc. RITUXAN HYCELA rituximab and hyaluronidase human Injection 761064 June 22, 2017 ⤷  Try for Free 2023-07-24
>Applicant>Tradename>Biologic Ingredient>Dosage Form>BLA>Approval Date>Patent No.>Expiredate
Showing 1 to 5 of 5 entries

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.